RUTHERFORD, N.J., Aug. 8, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time to discuss the second quarter financial results, the closing of the Gentris acquisition, the proposed FDA regulatory framework, and to answer questions.
Conference Call & Webcast
Thursday, August 14, 2014 at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
| Domestic: | 877-407-4018 | ||
| International: | 201-689-8471 | ||
| Conference ID: | 13587677 | ||
| Webcast: | http://www.cancergenetics.com | ||
| Replays – Available through August 28, 2014 | |||
| Domestic: | 877-870-5176 | ||
| International: | 858-384-5517 | ||
| Conference ID: | 13587677 | ||
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.